January 2, 2020

Opsens Inc.
% Chris Henza
Regulatory Consultant
Ultra LifeScience Solutions Inc.
872 S. Milwaukee Ave #286
Libertyville, Illinois 60048

Re: K191907

Trade/Device Name: OptoWire III
Regulation Number: 21 CFR 870.1330
Regulation Name: Catheter Guide Wire
Regulatory Class: Class II
Product Code: DQX, DXO
Dated: November 28, 2019
Received: December 3, 2019

Dear Chris Henza:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combo"nation-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Shawn W.
Forrest -S

Stephen Browning
Assistant Director
DHT2A: Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices
OHT2: Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known)
K191907

Device Name
OptoWire III

Indications for Use (Describe)
The OptoWire III pressure guidewire is indicated for use to measure pressure in blood vessels including both coronary and peripheral vessels, during diagnostic angiography and/or any interventional procedures. Blood pressure measurements provide hemodynamic information, such as fractional flow reserve, for the diagnosis and treatment of blood vessel disease.

Type of Use (Select one or both, as applicable)

- [x] Prescription Use (Part 21 CFR 801 Subpart D)
- [ ] Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”
5 510(k) Summary OptoWire III

1. SUBMITTER
   Address: Opsens, Inc.
   750, Boulevard du Parc Technologique
   Quebec (Quebec) G1P 4S3
   Phone: 418.781.0333 ext 3408
   Fax Number: 418-781-0024
   Contact Person: Marc Chaunet, Regulatory Affairs and Quality System Director
   Email: marc.chaunet@opsens.com
   Date Prepared: July 12, 2019

2. DEVICE
   Name of Device: OptoWire III
   Common or Usual Name: Pressure Guidewire
   Classification name: Wire, guide, catheter; Transducer, pressure, catheter tip
   Regulatory Class: II
   Product Code: DQX, DXO

3. PREDICATE DEVICE
   OptoWire Deux cleared via K152991 (cleared on 02/11/2016). This predicate has not been subject to a
design-related recall. No reference devices were used in this submission.

4. DEVICE DESCRIPTION
   The proposed OptoWire III is a new version of the OptoWire Deux that includes changes to strengthen
the robustness of the product. Additional changes have been made to improve manufacturability.
Changes include a reduction in tip length and coil gap, changes in the tube inner and outer
configuration, and a minor material change in the PTFE coating.

   The Opsens OptoWire III is used in conjunction with the Opsens OptoMonitor and Accessories, the
“OptoMonitor System” consisting of an electronic signal processing and display units (OptoMonitor) that
process signals received from the OptoWire to display intravascular blood pressure and hemodynamic
information, such as fractional flow reserve (FFR) values, and various connection cables. The
OptoMonitor is cleared in a separate 510(k), K142598.
The OptoWire III consists of the following items:

1. OptoWire assembly (guidewire) including the pressure sensor sub-assembly
2. Fiber Optic Interface Cable (FOIC)
3. Packaging including tray, Torque Device, pouch and box
4. Labelling including labels and printed IFU

5. **INDICATIONS FOR USE**
   To measure pressure in blood vessels including both coronary and peripheral vessels, during diagnostic angiography and/or other any interventional procedures. Blood pressure measurements provide hemodynamic information, such as fractional flow reserve, for the diagnosis and treatment of blood vessel disease.

6. **COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE**
   The proposed OptoWire III is substantially equivalent to the OptoWire Deux pressure guidewire cleared in K152991 on Feb 11, 2016.

   The proposed OptoWire III is a new version of the pressure guidewire that includes design changes from OptoWire Deux to OptoWire III (also referred to as OptoWire 3, OW 3, or OptoWire San (OW San)) is to strengthen the robustness of the wire. Additional changes were simultaneously implemented to optimize the manufacturing process. The proposed device and the predicate device are considered catheter guide wires and pressure transducer tips which are coded as DQX & DXO.

   Indications for Use for the OptoWire III are exactly the same as the predicate device indications (K152991 on Feb 11, 2016).

   The technological characteristics of the proposed OptoWire III include a reduction in tip length and coil gap, changes in the tube inner and outer configuration, and a minor material change in the PTFE coating. The changes have been evaluated through the Risk Management Process and no new questions of safety and effectiveness were identified. Existing questions of safety and effectiveness are valid for the proposed device. Any change raises a question concerning whether its performance can be expected to be equivalent with the predicate. Performance testing has confirmed equivalence. No new questions of safety and effectiveness were identified during the execution of Verification and Validation activities.

   Therefore, the proposed device, OptoWire III, meets substantial equivalence requirements with regards to the legally marketed predicate OptoWire Deux (K152991 cleared on Feb 11, 2016).

   For detailed comparison, refer to the Substantial Equivalence table on the following pages.
<table>
<thead>
<tr>
<th>Regulatory Information</th>
<th>Proposed Device</th>
<th>Predicate Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>OptoWire III</td>
<td>OptoWire Deux</td>
</tr>
<tr>
<td>510(k)#</td>
<td>Pending</td>
<td>K152991</td>
</tr>
<tr>
<td>Predicates</td>
<td>K152991</td>
<td>K142598</td>
</tr>
<tr>
<td>Product Code</td>
<td>DQX, DXO</td>
<td>DQX, DXO</td>
</tr>
<tr>
<td>Class</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Regulation Number</td>
<td>870.1330, 870.2870</td>
<td>870.1330, 870.2870</td>
</tr>
<tr>
<td>Regulation Generic Name</td>
<td>Wire, guide, catheter; Transducer, pressure, catheter tip</td>
<td>Wire, guide, catheter; Transducer, pressure, catheter tip</td>
</tr>
<tr>
<td>Intended Use</td>
<td>Coiled wire fits inside a percutaneous catheter for the purpose of directing the catheter through a blood vessel. Catheter tip transmits mechanical or electrical property changes in relation to changes in blood pressure to accessory equipment for processing.</td>
<td>Coiled wire fits inside a percutaneous catheter for the purpose of directing the catheter through a blood vessel. Catheter tip transmits mechanical or electrical property changes in relation to changes in blood pressure to accessory equipment for processing.</td>
</tr>
<tr>
<td>Indications</td>
<td>To measure pressure in blood vessels including both coronary and peripheral vessels, during diagnostic angiography and/or other any interventional procedures. Blood pressure measurements provide hemodynamic information, such as fractional flow reserve, for the diagnosis and treatment of blood vessel disease.</td>
<td>To measure pressure in blood vessels including both coronary and peripheral vessels, during diagnostic angiography and/or other any interventional procedures. Blood pressure measurements provide hemodynamic information, such as fractional flow reserve, for the diagnosis and treatment of blood vessel disease.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Technological Characteristics</th>
<th>Proposed Device</th>
<th>Predicate Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Use</td>
<td>Rx Only</td>
<td>Rx Only</td>
</tr>
<tr>
<td>System Components</td>
<td>Sterile, disposable guidewire</td>
<td>Sterile, disposable guidewire</td>
</tr>
<tr>
<td>System Capabilities</td>
<td>Measurement of intravascular blood pressure and flow including FFR. (when used with the OptoMonitor system)</td>
<td>Measurement of intravascular blood pressure and flow including FFR. (when used with the OptoMonitor system)</td>
</tr>
<tr>
<td>Sterile, Single Use Patient Contact Component?</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Guidewire OD</td>
<td>0.014”</td>
<td>0.014”</td>
</tr>
<tr>
<td>Guidewire Length</td>
<td>180 cm</td>
<td>175 cm</td>
</tr>
<tr>
<td>Guidewire Shaft Material</td>
<td>Stainless Steel, Nitinol</td>
<td>Nitinol</td>
</tr>
<tr>
<td>Guidewire Shaft Design</td>
<td>Two tubes joined by a laser butt weld</td>
<td>Continuous outer tube supported by safety wires</td>
</tr>
<tr>
<td>Guidewire Shaft Coating</td>
<td>Teflon (PTFE)</td>
<td>Teflon (PTFE)</td>
</tr>
<tr>
<td>Guidewire Intermediate Section Coating</td>
<td>PET + Hydrophilic coating</td>
<td>PET + Hydrophilic coating</td>
</tr>
<tr>
<td>Proposed Device</td>
<td>Predicate Device</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Guidewire Tip section Coating</strong></td>
<td>Uncoated</td>
<td>Uncoated</td>
</tr>
<tr>
<td><strong>Guidewire Tip Configuration</strong></td>
<td>Straight</td>
<td>Straight</td>
</tr>
<tr>
<td><strong>Guidewire Tip Design</strong></td>
<td>Coiled</td>
<td>Coiled</td>
</tr>
<tr>
<td><strong>Guidewire Tip Length</strong></td>
<td>3.0 cm</td>
<td>3.5 cm</td>
</tr>
<tr>
<td><strong>Radiopaque Tip?</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Pressure Sensor Location</strong></td>
<td>3.0 cm from distal tip</td>
<td>3.5 cm from distal tip</td>
</tr>
<tr>
<td><strong>Pressure Sensor Bonding</strong></td>
<td>Stainless steel 304 ring, laser welded</td>
<td>Glass ring + adhesive</td>
</tr>
<tr>
<td><strong>OptoWire Optical Connector</strong></td>
<td>Adhesive</td>
<td>Connector capillary ring + adhesive</td>
</tr>
<tr>
<td><strong>FFR Capability</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Basis for FFR Determination</strong></td>
<td>Simultaneous acquisition of 2 pressure values: distal pressure from sensor embedded in OptoWire; aortic pressure from external pressure transducer</td>
<td>Simultaneous acquisition of 2 pressure values: distal pressure from sensor embedded in OptoWire; aortic pressure from external pressure transducer</td>
</tr>
<tr>
<td><strong>Pressure Range</strong></td>
<td>-30 to 300 mmHg</td>
<td>-30 to 300 mmHg</td>
</tr>
<tr>
<td><strong>Pressure Accuracy</strong></td>
<td>+/- 1 mmHg plus +/-1% of reading (pressure range -30 to 50 mmHg) or +/-3% of reading (pressure range 50 to 300 mmHg)</td>
<td>+/- 1 mmHg plus +/-1% of reading (pressure range -30 to 50 mmHg) or +/-3% of reading (pressure range 50 to 300 mmHg)</td>
</tr>
<tr>
<td><strong>Thermal Zero Shift</strong></td>
<td>&lt;0.3 mmHg/deg C</td>
<td>&lt;0.3 mmHg/deg C</td>
</tr>
<tr>
<td><strong>Zero Drift</strong></td>
<td>&lt;1 mmHg/h</td>
<td>&lt;1 mmHg/h</td>
</tr>
</tbody>
</table>

7. **PERFORMANCE DATA**

**Risk Based Approach**

The Risk Management Report was prepared to document the evaluations and decisions made as well as necessary safety measures in the design and the manufacturing of the OptoWire III. Many of the risks are mitigated by design, labels, sterilization, packaging, and shelf life, and biocompatibility.

Since the OptoWire III is the third generation of the OptoWire device, the risk management process has leveraged the activities of previous generation OptoWire Deux device risk management process activities. The risk Management Report addresses the differences between the predicate/proposed device and specifically consider the impact of these changes including their intent as an improvement.
The risks related to all applicable hazards which were identified for the OptoWire III have been reduced to the acceptable level by mitigation. The OptoWire III is shown to be at least as safe and effective as the predicate device and the inherent risks are believed to be overcome by the benefits of the device use as indicated. Therefore, all residual risks post-mitigation have been deemed acceptable for this design.

**Sterilization, Packaging, Shelf life Testing:**

The following standards are utilized to show equivalence of Sterilization, Packaging, and Shelf life:

- ISO 11607-1 Packaging for terminally sterilized medical devices - part 1: requirements for materials, sterile barrier systems and packaging systems [including: amendment 1 (2014)]. (Sterility)
- ASTM F1980-07 (Reapproved 2011), standard guide for accelerated aging of sterile barrier systems for medical devices. (Sterility)

**Biocompatibility testing:**

The biocompatibility evaluation was conducted in accordance with the FDA guidance *Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process”* (Attachment A) published June 16, 2016. This device is categorized in *ISO 10993-1:2018* as “External communicating device – circulating blood” per section 5.2.3 c). The device will have limited exposure, a cumulative sum of single, multiple or repeated duration of contact up to 24 h. Testing completed on this device includes:

- Cytotoxicity
- Sensitization
- Intracutaneous reactivity
- Systemic toxicity (acute)
- Hemocompatibility
- Pyrogenicity (rabbit test)
- SC5b-9 complement
- Partial Tromboplastin Time

**Design Verification Pre-Conditioning:**

The OptoWire III devices were exposed to EtO and Simulated Distribution prior to the execution of testing as pre-conditioning. Additionally, testing with the indicator “T1” was completed on devices subjected to accelerated aging the equivalent of 1 year (“T0” = no aging).

**Design Verification:**

Testing was conducted based on requirements of the latest FDA guidance document on guidewires: FDA Draft Guidance Coronary, Peripheral, and Neurovascular Guidewire, dated June 15, 2018. All Design Requirements were verified for the OptoWire III.

Design Specification Verification and ISO 11070 Compliance were completed by documentation check and therefore did not use any OptoWire III product.
The Fiber Optic Interface Cable and Sensor are tested at a component level as some verification items are difficult or not possible to assess once the components are built into the OptoWire III.

The Design Check and Functional testing are performed on finished devices with pre-conditioning. Since the design check consists of physical measurements and inspections, the test is only completed on unaged products. The Functional testing is completed on both unaged (T0) and aged (T1) products.

Mechanical Performance testing are performed on finished devices with pre-conditioning as specified in the protocols. Certain tests that relate to improvements from the OptoWire Deux also include a comparison to the predicate device (without any pre-conditioning). These tests include: Mechanical tests for Tip Flexibility, Tensile Strength, Torquability, Catheter Compatibility, Kink Resistance test, Bending test, Coating Pushability and Durability. The Mechanical testing is completed on both unaged (T0) and aged (T1) products.

No new questions of safety and effectiveness were identified during review of Risk Management documentation or execution of Verification and Validation activities.

**Animal studies:**

Animal performance testing was completed to validate device functionality. The animal model was a porcine model (Sus scrofa – Hybrid farm pigs). A non-atherosclerotic swine model was chosen because the model has been used extensively for angiographic/pressure studies, resulting in a large volume of data on its vascular response and correlation to humans. The study included 1 female pig and one spare animal that was not used.

The performance of the Optowire III was compared to the Optowire Deux in the LCx, LAD and LAD side branches. The evaluation consisted of tests to confirm compatibility with coronary arteries by examining the following criteria:

1. Guidewire atraumaticity
   - Tip flexibility
   - Guidewire flexibility

2. Trackability
   - Steerability
   - Torquability

Pushability

3. Catheter compatibility
   - Restriction
   - Support (deliverability)

4. Stent compatibility

5. Radiopacity and pressure waveform

Results were recorded as less than average, average, greater than average, and “workhorse”. The OptoWire III obtained a 'workhorse' score for most of the parameters evaluated and demonstrated a similar performance as the control, OptoWire Deux, for the pressure waveform and radiopacity. It can be concluded based on the results that the OptoWire III is substantially equivalent to the control.
8. CONCLUSIONS

The results from these tests mentioned above demonstrate that the technological and performance characteristics of the proposed OptoWire III is comparable to the predicate device, support the safety and effectiveness of the device that is the subject of this 510(k), and ensure the subject device can perform in a manner equivalent to the predicate device with the same intended use.

The results of the verification/validation tests and the risk analysis have demonstrated that the OptoWire III does not raise any new questions of safety and efficacy and is therefore substantially equivalent to the predicate OptoWire Deux (K152991 on Feb 11, 2016).